Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab
Publication date: December 2026 Source: Seminars in Oncology, Volume 53, Issue 6 Author(s): Margherita Rimini, Simone Rocchetto, Eleonora Alimenti, Giuseppe Cabibbo, Lorenza Rimassa, David J. Pinato, Alessandro Vitale, Francesca R. Ponziani, Silvia Camera, Mara Persano, Pietro Lampertico, Andrea Casadei-Gardini, Massimo Iavarone
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. // Seminars in Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Seminars in Oncology. https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
“Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab.” Seminars in Oncology.
@article{article65824,
title = {Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab},
journal = {Seminars in Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all}
}
ABSTRACT Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study...
Abstract Background and Objectives Perioperative blood transfusion in hip arthroplasty is associated with increased morbidity, prolonged hospitalization, and higher costs. This study aimed to identify independent risk factors and...